



Press release

ZENEO® Midazolam clinical study: completion of the injection phase

Dijon, 19 July 2022

CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharma company developing and soon to market a portfolio of drugs for use in emergency situations, announces the end of the injection phase of the bioequivalence clinical study for ZENEO® Midazolam.

All injections of ZENEO® Midazolam planned as part of the clinical bioequivalence study have been completed on schedule. This phase went very smoothly. 40 subjects were included for the evaluation of the pharmacokinetics of Midazolam 10 mg, which is intended to stop epileptic seizures.

Following these injections, bioanalysis, data management and statistical work will take place in order to obtain the complete results of the bioequivalence study in the autumn.

As a reminder: The objective of the study is to compare the plasma concentration of a ZENEO® Midazolam injection in healthy subjects with that of a syringe fitted with a conventional intramuscular needle and syringe filled with the regulatory reference drug Midazolam. The results of this study will be presented in the Marketing Authorisation Application (MAA).

Patrick Alexandre, Crossject CEO, said: *"I would like to thank the Crossject teams and those of our CRO¹ for the successful completion of this phase of the clinical bioequivalence study. Our collective commitment allows us to move ahead on our roadmap in accordance with our schedule."*

Next release: 20 September 2022 (after trading): First-half 2022 results

¹ Contract Research Organization.



Contacts:

Crossject
Patrick Alexandre
info@crossject.com

Investor relations
CIC Market Solutions
Catherine Couanau +33 (0)1 53 48 81 97
catherine.couanau@cic.fr

Press relations
Buzz & Compagnie
Mélanie Voisard +33 (0)3 80 43 54 89
melanie.voisard@buzzetcompagnie.com
Christelle Distinguin +33 (0)3 80 43 54 89
christelle.distinguin@buzzetcompagnie.com

About CROSSJECT • www.crossject.com

Crossject (ISIN: FR0011716265; Ticker: ALCJ; LEI: 969500W1VTFNL2D85A65) is developing and is soon to market a portfolio of drugs dedicated to emergency situations: epilepsy, overdose, allergic shock, severe migraine and asthma attack. Thanks to its patented needle-free self-injection system, Crossject aims to become the world leader in self-administered emergency drugs. The company has been listed on the Euronext Growth market in Paris since 2014, and benefits from Bpifrance funding.